[{"orgOrder":0,"company":"Afaxys Pharma","sponsor":"The David and Lucile Packard Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2025","type":"Funding","leadProduct":"Medroxyprogesterone Acetate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Afaxys Pharma","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Afaxys Pharma \/ The David and Lucile Packard Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Afaxys Pharma \/ The David and Lucile Packard Foundation"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"FHI 360","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"ISRAEL","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Medroxyprogesterone Acetate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ FHI 360","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharmaceutical Industries \/ FHI 360"},{"orgOrder":0,"company":"Ginefiv","sponsor":"Theramex","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Medroxyprogesterone Acetate","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Ginefiv","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginefiv \/ Theramex","highestDevelopmentStatusID":"11","companyTruncated":"Ginefiv \/ Theramex"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Expanded Collaboration","leadProduct":"Medroxyprogesterone Acetate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Bill & Melinda Gates Foundation"}]

Find Clinical Drug Pipeline Developments & Deals for CAS-71-58-9

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The funding will be used to complete the development of a novel contraceptive product, MSQA, an auto-injectable contraceptive containing medroxyprogesterone.

                          Product Name : MSQA

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          August 04, 2025

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Undisclosed

                          Sponsor : The David and Lucile Packard Foundation

                          Deal Size : $8.0 million

                          Deal Type : Funding

                          blank

                          02

                          Ginefiv

                          Country arrow
                          Fall Technical Meeting
                          Not Confirmed

                          Ginefiv

                          Country arrow
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Medroxyprogesterone Acetate is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Embryo.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          October 15, 2024

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Theramex

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : The expanded collaboration is expected to deliver more than 320 million doses of Pfizer’s injectable contraceptive, Sayana Press (medroxyprogesterone acetate) administered by BD Uniject™ Auto-Disable Prefillable Injection System, through 2030.

                          Product Name : Sayana Press

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          August 03, 2023

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Bill & Melinda Gates Foundation

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank

                          04

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : TV-46046 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Contraception.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          December 23, 2020

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase I

                          Sponsor : FHI 360

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank